Temozolomide
Back to searchMolecule Structure
Scientific Name
Temozolomide
Description of the Drug
Temozolomide is an alkylating agent used to treat glioblastoma multiforme and refractory anaplastic astrocytoma.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00853
http://www.drugbank.ca/drugs/DB00853
Brand Name(s)
Temodal, Temodar, Temomedac, Temozolomide
Company Owner(s)
Apotex Inc, Heritage Pharma Labs Inc Dba Avet Pharma Labs Inc, Watson Laboratories Inc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc, Sun Pharmaceutical Industries Ltd, Merck Sharp And Dohme Corp, Nivagen Pharmaceuticals Inc, Accord Healthcare Inc, Ani Pharmaceuticals Inc, Amneal Pharmaceuticals, Chemi Spa
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2311221 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL3739 | ||
| PharmGKB | PA451609 | ||
| Human Metabolome Database | HMDB0014991 | ||
| DrugBank | DB00853 | ||
| PubChem: Thomson Pharma | 15171582 | ||
| PubChem | 5394 | ||
| Mcule | MCULE-9414994158 | ||
| LINCS | LSM-4590 | ||
| Nikkaji | J171.234I | ||
| BindingDB | 50034562 | ||
| EPA CompTox Dashboard | DTXSID5043714 | ||
| DrugCentral | 2589 | ||
| Brenda | 230129 | 230130 | 18217 |
| ChemicalBook | CB2708199 | ||
| Guide to Pharmacology | 7301 | ||
| rxnorm | TEMOZOLOMIDE | TEMODAR | |
| PubChem: Drugs of the Future | 12013608 | ||
| ChEBI | 72564 | ||
| ZINC | ZINC000001482184 |
